
Improving Cancer Care: Potential for Enhanced Immunotherapy Treatment Identified
Improving Cancer Care: Potential for Enhanced Immunotherapy Treatment Identified
A breakthrough study by Brigham and Women’s Hospital researchers suggests that by revising existing cancer care protocols, an estimated 6,000 more cancer patients in the United States annually could benefit from immunotherapy treatment.
The study, published in Cancer Cell, revealed that the current standard diagnostic test for mismatch repair deficiency, immunohistochemistry, missed detecting nearly 6% of endometrial cancer and 1% of colorectal cancer patients with this condition. These overlooked cases could potentially be identified through next-generation sequencing, thus expanding the pool of patients eligible for immunotherapy.
Dr. Elias Bou Farhat, the study’s first author, emphasized the significance: “Patients with mismatch repair deficiency respond remarkably to immunotherapy, even in advanced cancer stages, sometimes achieving long-term remission or even potential cure.”
Colorectal and endometrial cancers commonly exhibit high rates of mismatch repair deficiency, impairing DNA repair and leading to cancer. Immunotherapy, leveraging the body’s immune system, has shown promising results in these patients. However, the study highlighted that immunohistochemistry, the current standard test, may miss crucial cases identified by next-generation sequencing.
The research analyzed 1,655 patients from Brigham and Women’s Hospital and Dana-Farber Cancer Institute, finding that patients identified as mismatch repair deficient via sequencing but missed by immunohistochemistry showed similar positive responses to immunotherapy. This suggests the need for a more sensitive diagnostic tool like next-generation sequencing.
Dr. Amin Nassar, the study’s senior author, underscored the importance of accurate diagnoses to avoid ineffective or potentially harmful treatments, stressing the importance of providing suitable therapies.
While the findings propose next-generation sequencing as a more sensitive diagnostic method, further research is essential for validation and broad application. The study also highlighted better treatment outcomes for patients receiving immunotherapy compared to those who did not, emphasizing the criticality of identifying candidates for this treatment.
Future research aims to explore wider applicability in different cancer types and additional genetic deficiencies linked to mismatch repair deficiency, ultimately seeking to enhance cancer care through precise and effective treatment approaches.
Latest Posts
- US Senate Panel Set to Review Todd Blanche for Attorney General
August 1, 2026 | Breaking News, Politics, World - Fintech Chime Cuts 10 Percent of Workforce as AI Reshapes Operations
August 1, 2026 | Breaking News, Business, Stock Market - Jammu Kashmir: Cloudburst Hits Chatroo in Kishtwar; NH-244 Closed as Precaution
August 1, 2026 | Breaking News, Jammu Kashmir, Kishtwar - Tanker Hit by Unknown Projectile Off Oman, UK Maritime Agency Says
August 1, 2026 | Breaking News, World - Hedge fund Millennium looks to raise record $20 billion in new capital, source says
August 1, 2026 | Breaking News, Business, Stock Market - India Draws $40.81 Billion After RBI’s Foreign Exchange Reforms
August 1, 2026 | Breaking News, Business, Stock Market - Schools Closed in Doda, Kishtwar and Ramban Today Amid Adverse Weather, Online Classes to Continue
August 1, 2026 | Breaking News, Jammu Kashmir - Saudi Arabia Launches 14-Nation Maritime Defence Alliance to Secure Bab al-Mandab Straits and Red Sea Shipping Routes
July 31, 2026 | Breaking News, Israel Palsteine Conflict, World - Kuwait Says It Intercepted Iranian Drones Targeting Vital Facilities
July 31, 2026 | Breaking News, Israel Palsteine Conflict, World - Crackdown on Pakistan-occupied Kashmir Protesters, India Slams Pakistan
July 31, 2026 | Breaking News, Politics, World